Estrella Immunopharma (ESLA) Competitors $0.84 +0.02 (+2.02%) Closing price 08/5/2025 03:50 PM EasternExtended Trading$1.05 +0.21 (+24.26%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. TARA, TNYA, IKT, ANEB, BHST, FTLF, SPRO, CRDL, ATOS, and CHRSShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Protara Therapeutics (TARA), Tenaya Therapeutics (TNYA), Inhibikase Therapeutics (IKT), Anebulo Pharmaceuticals (ANEB), BioHarvest Sciences (BHST), FitLife Brands (FTLF), Spero Therapeutics (SPRO), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Protara Therapeutics Tenaya Therapeutics Inhibikase Therapeutics Anebulo Pharmaceuticals BioHarvest Sciences FitLife Brands Spero Therapeutics Cardiol Therapeutics Atossa Genetics Coherus Oncology Estrella Immunopharma (NASDAQ:ESLA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Do institutionals & insiders believe in ESLA or TARA? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ESLA or TARA? Estrella Immunopharma has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Do analysts prefer ESLA or TARA? Estrella Immunopharma currently has a consensus price target of $16.00, indicating a potential upside of 1,793.49%. Protara Therapeutics has a consensus price target of $20.50, indicating a potential upside of 550.79%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is ESLA or TARA more profitable? Protara Therapeutics' return on equity of -36.37% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -273.91% Protara Therapeutics N/A -36.37%-33.29% Does the media favor ESLA or TARA? In the previous week, Protara Therapeutics had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Protara Therapeutics and 0 mentions for Estrella Immunopharma. Protara Therapeutics' average media sentiment score of 0.11 beat Estrella Immunopharma's score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral Protara Therapeutics Neutral Which has better earnings and valuation, ESLA or TARA? Estrella Immunopharma is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.25Protara TherapeuticsN/AN/A-$44.60M-$1.72-1.83 SummaryProtara Therapeutics beats Estrella Immunopharma on 10 of the 14 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.96M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.71%4.14%P/E Ratio-3.2517.5328.8923.88Price / SalesN/A313.17447.6498.82Price / CashN/A42.6035.6858.35Price / Book7.047.828.165.60Net Income-$7.31M-$54.52M$3.25B$265.26M7 Day Performance-3.43%2.86%1.12%-0.15%1 Month Performance-8.55%17.29%8.22%6.07%1 Year Performance-41.32%13.27%29.12%24.21% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma2.3903 of 5 stars$0.85+2.0%$16.00+1,793.5%-40.5%$29.96MN/A-3.25N/ATARAProtara Therapeutics2.0653 of 5 stars$3.33-0.6%$20.50+515.6%+52.2%$128.48MN/A-1.9430Positive NewsTNYATenaya Therapeutics3.5196 of 5 stars$0.70-9.7%$6.25+787.5%-72.7%$126.86MN/A-0.61110Analyst RevisionIKTInhibikase Therapeutics1.3895 of 5 stars$1.70-4.0%$6.50+282.4%+31.4%$126.38MN/A-0.646ANEBAnebulo Pharmaceuticals1.619 of 5 stars$3.06-2.5%$5.50+79.7%+37.5%$125.72MN/A-11.774BHSTBioHarvest SciencesN/A$7.56+0.8%$13.67+80.8%N/A$124.14M$25.19M-15.12N/ANews CoverageFTLFFitLife Brands3.5769 of 5 stars$13.13+2.3%$20.50+56.1%+5.1%$123.30M$63.86M15.6320News CoverageGap UpSPROSpero Therapeutics3.8602 of 5 stars$2.20-4.3%$5.00+127.3%+58.2%$123.00M$47.98M-1.72150News CoverageCRDLCardiol Therapeutics2.1219 of 5 stars$1.46-4.6%$8.00+447.9%-30.4%$120.67MN/A-4.2920News CoverageUpcoming EarningsHigh Trading VolumeATOSAtossa Genetics2.5982 of 5 stars$0.92+13.1%$6.17+567.0%-30.0%$119.42MN/A-4.408News CoverageUpcoming EarningsHigh Trading VolumeCHRSCoherus Oncology3.9372 of 5 stars$1.01-5.6%$4.68+363.7%-31.0%$117.09M$266.96M-0.89330Upcoming EarningsGap Up Related Companies and Tools Related Companies Protara Therapeutics Competitors Tenaya Therapeutics Competitors Inhibikase Therapeutics Competitors Anebulo Pharmaceuticals Competitors BioHarvest Sciences Competitors FitLife Brands Competitors Spero Therapeutics Competitors Cardiol Therapeutics Competitors Atossa Genetics Competitors Coherus Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLA Stock Alerts